NASDAQ$RNA

Atrium Therapeutics Inc · Q2 2023 earnings

Q2 2023 earnings ·

Headline financials

Total Revenue

$2.32M

Previous: $2.18M+6.3%
EPS

-$0.66

Previous: -$0.92+28.3%
Capital Expenditures

-$2.44M

Previous: -$2.08M-17.4%
Free Cash Flow

-$49.5M

Previous: -$47.8M-3.6%
Net Income

-$47M

Previous: -$45.7M-2.9%
Operating Income

-$52.6M

Previous: -$46.3M-13.7%
Gross Profit

$0.00

Previous: $0.00

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$2.32M

Q2 2023+6.3%vs Q2 2022
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro